Page 264 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 264
Viral Hepatitis: Hepatitis C - Clinical (Therapy) (Cont.)
P0827 A DESCRIPTIVE ANALYSIS OF A REAL-WORLD
POPULATION WITH CHRONIC HEPATITIS C (CHC)
TREATED WITH SIMEPREVIR (SMV)- AND/OR SOFOSBUVIR
(SOF)-BASED REGIMENS: FINDINGS FROM A US PAYER
DATABASE
Jamie B. Forlenza, Jonathan Fortier, François Laliberté, Patrick Lefebvre,
Neeta Tandon*, The United States
P0828 RELAPSERS TO NON-INTERFERON, SOVALDI BASED
TREATMENT OF G1 CHRONIC HCV WERE INADEQUATELY
TREATED
John C. Hoefs*, Lien T. Tran, Behnaz B. Babaknia, The United States
P0829 ON-TREATMENT HCV RNA AS A PREDICTOR OF
SUSTAINED VIROLOGIC RESPONSE IN HCV GENOTYPE 3
ePOSTERS INFECTED PATIENTS TREATED WITH DACLATASVIR AND
SOFOSBUVIR: ANALYSIS OF PHASE 3 ALLY-3 STUDY
Kris Kowdley*, David Nelson, Jacob Lalezari, Terry Box, Norman Gitlin,
Gary Poleynard, Mordechai Rabinovitz, Natarajan Ravendhran,
Aasim Sheikh, Asma Siddique, Rafia Bhore, Philip D. Yin,
Stephanie Noviello, Khurram Rana, The United States
P0830 EARLY HCV KINETICS DURING DUAL ORAL THERAPY
WITH DACLATASVIR AND ASUNAPREVIR
Makoto Nakamuta*, Motoyuki Kohjima, Kenta Motomura, Shinji Tabata,
Toshimasa Koyanagi, Naoki Yamashita, Takeaki Sato, Masaki Yokota,
Nobito Higuchi, Tsuyoshi Yoshimoto, Tomoyuki Kurashige,
Mio Kawamoto, Kunitaka Fukuizumi, Kazuhiro Kotoh, Japan
P0831 SAFETY AND EFFICACY OF SOFOSBUVIR-BASED
TREATMENT REGIMENS FOR CHRONIC HEPATITIS C
VIRUS INFECTION: A “REAL-LIFE”, SINGLE-CENTER
EXPERIENCE IN 117 PATIENTS
Malte H. Wehmeyer*, Christiane Eißing, Sabine Jordan, Ansgar W. Lohse,
Julian Schulze zur Wiesch, Stefan Lüth, Germany
P0833 SIMEPREVIR- AND TELAPREVIR- BASED TRIPLE
THERAPIES FOR GENOTYPE 1B CHRONIC HEPATITIS
C PATIENTS AGED 70 AND OVER IN A MULTICENTRE
COHORT STUDY
Norihiro Furusyo*, Eiichi Ogawa, Eiji Kajiwara, Hideyuki Nomura,
Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh,
Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi,
Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Japan
264 The International Liver Congress™ 2015 • ILC Programme
P0827 A DESCRIPTIVE ANALYSIS OF A REAL-WORLD
POPULATION WITH CHRONIC HEPATITIS C (CHC)
TREATED WITH SIMEPREVIR (SMV)- AND/OR SOFOSBUVIR
(SOF)-BASED REGIMENS: FINDINGS FROM A US PAYER
DATABASE
Jamie B. Forlenza, Jonathan Fortier, François Laliberté, Patrick Lefebvre,
Neeta Tandon*, The United States
P0828 RELAPSERS TO NON-INTERFERON, SOVALDI BASED
TREATMENT OF G1 CHRONIC HCV WERE INADEQUATELY
TREATED
John C. Hoefs*, Lien T. Tran, Behnaz B. Babaknia, The United States
P0829 ON-TREATMENT HCV RNA AS A PREDICTOR OF
SUSTAINED VIROLOGIC RESPONSE IN HCV GENOTYPE 3
ePOSTERS INFECTED PATIENTS TREATED WITH DACLATASVIR AND
SOFOSBUVIR: ANALYSIS OF PHASE 3 ALLY-3 STUDY
Kris Kowdley*, David Nelson, Jacob Lalezari, Terry Box, Norman Gitlin,
Gary Poleynard, Mordechai Rabinovitz, Natarajan Ravendhran,
Aasim Sheikh, Asma Siddique, Rafia Bhore, Philip D. Yin,
Stephanie Noviello, Khurram Rana, The United States
P0830 EARLY HCV KINETICS DURING DUAL ORAL THERAPY
WITH DACLATASVIR AND ASUNAPREVIR
Makoto Nakamuta*, Motoyuki Kohjima, Kenta Motomura, Shinji Tabata,
Toshimasa Koyanagi, Naoki Yamashita, Takeaki Sato, Masaki Yokota,
Nobito Higuchi, Tsuyoshi Yoshimoto, Tomoyuki Kurashige,
Mio Kawamoto, Kunitaka Fukuizumi, Kazuhiro Kotoh, Japan
P0831 SAFETY AND EFFICACY OF SOFOSBUVIR-BASED
TREATMENT REGIMENS FOR CHRONIC HEPATITIS C
VIRUS INFECTION: A “REAL-LIFE”, SINGLE-CENTER
EXPERIENCE IN 117 PATIENTS
Malte H. Wehmeyer*, Christiane Eißing, Sabine Jordan, Ansgar W. Lohse,
Julian Schulze zur Wiesch, Stefan Lüth, Germany
P0833 SIMEPREVIR- AND TELAPREVIR- BASED TRIPLE
THERAPIES FOR GENOTYPE 1B CHRONIC HEPATITIS
C PATIENTS AGED 70 AND OVER IN A MULTICENTRE
COHORT STUDY
Norihiro Furusyo*, Eiichi Ogawa, Eiji Kajiwara, Hideyuki Nomura,
Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh,
Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi,
Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Japan
264 The International Liver Congress™ 2015 • ILC Programme
